Recombinant viruses as vaccines and immunological tools

Current Opinion in Immunology

Volumn 9, Issue 4, 1997, Pages 517-524

  Rolph, Michael S ^a   Ramshaw, Ian A ^b  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 39; INTERLEUKIN 4; NITRIC OXIDE; VIRUS VACCINE; VIRUS VECTOR;

IMMUNOLOGY; POLIOMYELITIS VIRUS; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS RECOMBINANT;

EID: 0030874081     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80104-5     Document Type: Article

References (85)

1. Restifo NP. The new vaccines - building viruses that elicit antitumor immunity. Curr Opin Immunol. 8:1996;658-663.
2. Smith EA. Viral vectors in gene therapy. Annu Rev Microbiol. 49:1995;807-838.
3. Ada GL, McElrath MJ. HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy. AIDS Res Hum Retroviruses. 13:1997;205-210.
4. Pastoret PP, Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. of special interest Epidemiol Infect. 116:1996;235-240 Review describing the highly successful application of recombinant viruses for the control of wildlife rabies.
5. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 188:1992;217-232.
6. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA. 93:1996;11349-11353.
7. Lanar DE, Tine JA, Detaisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, et al. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun. 64:1996;1666-1671.
8. Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, Detaisne C, Hui G, Chang SP, et al. NYVAC-P17 - a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. of special interest Infect Immun. 64:1996;3833-3844 This paper describes the construction and immunogenicity testing of a recombinant, attenuated VV encoding seven different P. falciparum antigens from different stages of the parasite life cycle. It is a good example of the potential of recombinant viruses to encode multiple antigens.
9. Moss B. Genetically engineered poxviruses for recombinant gene expression. Proc Natl Acad Sci USA. 93:1996;11341-11348.
10. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12:1994;1032-1040.
11. Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, Small PA. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. of special interest J Virol. 70:1996;6418-6424 Demonstrating that rVV can be immunogenic following oral administration - an important advantage for any vaccine.
12. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M, Elkins WR, Alvord WG, Montefiori DC, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 70:1996;3741-3752.
13. Taylor J, Trimarchi C, Weinberg R, Languet B, Guillemin F, Desmettre P, Paoletti E. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine. 9:1991;190-193.
14. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol. 68:1994;8125-8130.
15. Konishi E, Pincus S, Paoletti E, Shope RE, Mason PW. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine. 12:1994;633-638.
16. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, Plotkin S. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 14:1996;428-434.
17. Stephenson CB, Welter J, Thaker SR, Taylor J, Tartaglia J, Paoletti E. Canine distemper virus (CDV) infection of ferrets as a model for testing morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol. 71:1997;1506-1513.
18. Andersson S, Makitalo B, Thorstensson R, Franchini G, Tartaglia J, Limbach K, Paoletti E, Putkonen P, Biberfeld G. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis. 174:1996;977-985.
19. MN env gene. J Infect Dis. 171:1995;1623-1627.
20. Pialoux G, Excler JL, Riviere Y, Gonzalezcanali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, Kieny MP, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses. 11:1995;373-381.
21. Imler JL. Adenovirus vectors as recombinant viral vaccines. Vaccine. 13:1995;1143-1151.
22. Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyamura T, Saito I. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine. 14:1996;28-34.
23. Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol. 25:1995;3467-3473.
24. Fooks AR, Schadeck E, Liebert UG, Dowsett AB, Rima BK, Steward M, Stephenson JR, Wilkinson G. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology. 210:1995;456-465.
25. Xiang ZQ, Yang YP, Wilson JM, Ertl H. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. of special interest Virology. 219:1996;220-227 A replication-deficient adenovirus encoding a rabies glycoprotein was capable of inducing particularly impressive rabies-specific antibody and CTL responses in mice.
26. Gonin P, Oualikene W, Foumier A, Eloit M. Comparison of the efficacy of replication defective adenovirus and NYVAC poxvirus as vaccine vectors in mice. Vaccine. 14:1996;1083-1087.
27. Mittal SK, Papp Z, Tikoo SK, Bacaestrada ME, Yoo D, Benko M, Babiuk LA. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpes virus type 1 glycoprotein gD. Virology. 222:1996;299-309.
28. Lubeck MD, Natuk RJ, Chengalvala M, Chanda PK, Murthy KK, Murthy S, Mizutani S, Lee SG, Wade MS, Bhat BM, et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses. 10:1994;1443-1449.
29. Yarosh OK, Wandeler AI, Graham FL, Campbell JB, Prevec L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine. 14:1996;1257-1264.
30. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med. 184:1996;1879-1890.
31. Andino R, Silvera D, Suggett SD, Achacoso PL, Miller CJ, Baltimore D, Feinberg MB. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science. 265:1994;1448-1451.
32. Yim TJ, Tang SB, Andino R. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice. of special interest Virology. 218:1996;61-70 See annotation [35].
33. Lu HH, Alexander L, Wimmer E. Construction and genetic analysis of dicistronic polloviruses containing open reading frames for epitopes of human immunodeficiency virus type 1 gp120. J Virol. 69:1995;4797-4806.
34. Porter DC, Melsen LR, Compans RW, Morrow CD. Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 gag. J Virol. 70:1996;2643-2649.
35. mac239 gag or envelope SU proteins. of special interest AIDS Res Hum Retroviruses. 13:1997;53-62 Along with [32], this paper demonstrates the potential use of recombinant poliovirus as a vaccine vector.
36. Evans DJ, McKeating J, Meredith JM, Burke KL, Katrak K, John A, Ferguson M, Minor PD, Weiss RA, Almond JW. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralising antibodies. Nature. 339:1989;385-388.
37. smmPBj14. Virology. 219:1996;140-149.
38. Moldoveanu Z, Porter DC, Lu AL, Mcpherson S, Morrow CD. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins. Vaccine. 13:1995;1013-1022.
39. Thomson SA, Elliott SL, Sherritt MA, Sproat KW, Coupar B, Scalzo AA, Forbes CA, Ladhams AM, Mo XY, Tripp RA, et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. of special interest J Immunol. 157:1996;822-826 See annotation [41].
40. + cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA. 92:1995;5845-5849.
41. An L, Whitton JL. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. of special interest J Virol. 71:1997;2292-2302 Along with [39], this paper demonstrates the potential utility of recombinant viruses presenting multiple minimal immunogenic epitopes. Each epitope was processed and presented effectively and, where tested, induced protective immune responses.
42. Whitton JL, Sheng N, Oldstone MB, McKee TA. A 'string-of-beads' vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol. 67:1993;348-352.
43. An LL, Pamer E, Whitton JL. A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listeria monocytogenes infection. Infect Immun. 64:1996;1685-1693.
44. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu S-L, Corey L. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 337:1991;567-572.
45. Taylor J, Meignier B, Tartaglia J, Languet B, Vanderhoeven J, Franchini G, Trimarchi C, Paoletti E. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 13:1995;539-549.
46. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis. 167:1993;533-537.
47. Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA. 90:1993;1882-1886.
48. Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, Paoletti E, Kieny MP, Excler JL, Riviere Y. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis. 174:1996;734-738.
49. Abimiku AG, Franchini G, Tartaglia J, Aldrich K, Myagkikh M, Markham PD, Chong PL, Klein M, Kieny MP, Paoletti E, et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med. 1:1995;321-329.
50. Myagkikh M, Alipanah S, Markham PD, Tartaglia J, Paoletti E, Gallo RC, Franchini G, Robert-Guroff M. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses. 12:1996;985-992.
51. Franchini G, Robert-Guroff M, Tartaglia J, Aggarwal A, Abimiku A, Benson J, Markham P, Limbach K, Hurteau G, Fullen J, et al. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res Hum Retroviruses. 11:1995;909-920.
52. + T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J Virol. 70:1996;4941-4947.
53. Leong KH, Ramsay AJ, Ramshaw IA, Morin MJ, Robinson HL, Boyle DB. Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowl pox vectors. Brown F, Chanock R, Ginsberg H, Norrby E. Vaccines 95. 1995;327-331 Cold Spring Harbor Press, Cold Spring Harbor.
54. Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature. 329:1987;545-546.
55. Flexner C, Hugin A, Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature. 330:1987;259-262.
56. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. of special interest J Virol. 70:1996;7103-7107 See annotation [62].
57. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today. 15:1994;575-581.
58. Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, Graham FL, Hitt M, Danforth JM, Standiford TJ. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol. 157:1996;3006-3012.
59. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, Kopf M. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science. 264:1994;561-563.
60. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. of special interest J Exp Med. 183:1996;195-201 See annotation [62].
61. Rolph MS, Ramshaw IA, Rockett KA, Ruby J, Cowden WB. Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance. Virology. 217:1996;470-477.
62. Rolph MS, Cowden WB, Medveczky CJ, Ramshaw IA. A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo. of special interest J Virol. 70:1996;7678-7685 This paper, along with [56,60], demonstrates the utility of recombinant viruses expressing immunoactive molecules as tools for basic immunological research.
63. Melkova Z, Esteban M. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J Immunol. 155:1995;5711-5718.
64. Wrighton CJ, Hoferwarbinek R, Moll T, Eytner R, Bach FH, Demartin R. Inhibition of endothelial cell activation by adenovirus-mediated expression of IκBα, an inhibitor of the transcription factor NFκB. J Exp Med. 183:1996;1013-1022.
65. Kolls JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis. 171:1995;570-575.
66. Ruby J, Bluethmann H, Aguet M, Ramshaw IA. CD40 ligand has potent antiviral activity. Nat Med. 1:1995;437-441.
67. Ehl S, Hoffmann-Rohrer U, Nagata S, Hengartner H, Zinkernagel R. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol. 156:1996;2357-2360.
68. Foley R, Driscoll K, Wan Y, Braciak T, Howard B, Xing Z, Graham F, Gauldie F. Adenoviral gene transfer of macrophage inflammatory protein-2 in rat lung. Am J Pathol. 149:1996;1395-1403.
69. Braciak TA, Bacon K, Xing Z, Torry DJ, Graham FL, Schall TJ, Richards CD, Croitoru K, Gauldie J. Overexpression of RANTES using a recombinant adenovirus vector induces the tissue-directed recruitment of monocytes to the lung. J Immunol. 157:1996;5076-5084.
70. Giavedoni LD, Yilma T. Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon. J Virol. 70:1996;2247-2251.
71. Giavedoni L, Ahmad S, Jones L, Yilma T. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. of outstanding interest J Virol. 71:1997;866-872 Expression of IFN-γ in a recombinant nef-deleted SIV was shown to result in increased virus attenuation. Following challenge with virulent SIV, virus titres were lower in macaques that had previously received the IFN-γ expressing SIV than in those that had received the control nef-deleted SIV.
72. Baba TW, Jeong YS, Penninck D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 267:1995;1820-1825.
73. Gundlach BR, Linhart H, Dittmer U, Sopper S, Reiprich S, Fuchs D, Fleckenstein B, Hunsmann G, Stahl-Hennig C, Überla K. Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol. 71:1997;2225-2232.
74. He XS, Chen HS, Chu KT, Rivkina M, Robinson WS. Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. Proc Natl Acad Sci USA. 93:1996;7274-7278.
75. Takao SI, Kiyotani K, Sakaguchi T, Fujii Y, Seno M, Yoshida T. Protection of mice from respiratory sendal virus infections by recombinant vaccinia viruses. J Virol. 71:1997;832-838.
76. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 93:1996;11341-11348.
77. Altmeyer R, Escriou N, Girard M, Palmenberg A, Vanderwerf S. Attenuated mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120. Proc Natl Acad Sci USA. 91:1994;9775-9779.
78. Altmeyer R, Girard M, Vanderwerf S, Mimic V, Seigneur L, Saron MF. Attenuated mengo virus: a new vector for live recombinant vaccines. J Virol. 69:1995;3193-3196.
79. Mossman SP, Bex F, Berglund P, Arthos J, O'Neil SP, Riley D, Maul DH, Bruck C, Momin P, Burny A, et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol. 70:1996;1953-1960.
80. Frolov I, Hoffman TA, Pragai BM, Dryga SA, Huang HV, Schlesinger S, Rice CM. Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci USA. 93:1996;11371-11377.
81. Zhou XZ, Berglund P, Zhao HX, Liljestrom P, Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci USA. 92:1995;3009-3013.
82. Pugachev KV, Mason PW, Shope RE, Frey TK. Double-subgenomic sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology. 212:1995;587-594.
83. Davis NL, Brown KW, Johnston RE. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol. 70:1996;3781-3787.
84. Muster T, Ferko B, Klima A, Purtscher M, Trkola A, Schulz P, Grassauer A, Engelhardt OG, Garci-Sastre A, Palese P, Katinger H. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol. 69:1995;6678-6686.
85. Palese P, Zheng H, Engelhardt OG, Pleschka S, Garcia-Sastre A. Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci USA. 93:1996;11354-11358.